Case Report
Korean J Hematol 2008; 43(2):
Published online June 30, 2008
https://doi.org/10.5045/kjh.2008.43.2.106
© The Korean Society of Hematology
R-CHOP 요법으로 치료한 장기이식 후 림프증식 질환 2예
윤설희, 김수정, 이혜원, 황도유, 김진석, 정준원, 민유홍
연세대학교 의과대학 내과학교실
Posttransplant Lymphoproliferative Disorders Successfully Treated with R-CHOP in Korea
Posttransplant lymphoproliferative disorder (PTLD) is a group of heterogeneous lymphoid diseases that cause serious complications after organ or stem cell transplantation. The onset of PTLD is mostly due to EBV infection-induced B-cell proliferation and a defect in cytotoxic T cell function that occurs with immunosuppression. The usual treatment strategy for PTLD is reduction or withdrawal of immunosuppressive drugs with or without the administration of antiviral agents. Recently, various studies on the efficacy of rituximab or chemotherapy have been reported. We report two cases of rapidly progressing and complicated PTLDs after kidney transplantation that were successfully treated with a combination regimen consisting of rituximab, cyclophosphamide, adriamycin, vincristine and prednisolone (R-CHOP). (Korean J Hematol 2008;43:106-112.)
Keywords Posttransplant, Lymphoproliferative, R-CHOP
PDF
Standard view
Export citation
Share Article
Case Report
Korean J Hematol 2008; 43(2): 106-112
Published online June 30, 2008 https://doi.org/10.5045/kjh.2008.43.2.106
Copyright © The Korean Society of Hematology.
R-CHOP 요법으로 치료한 장기이식 후 림프증식 질환 2예
윤설희, 김수정, 이혜원, 황도유, 김진석, 정준원, 민유홍
연세대학교 의과대학 내과학교실
Posttransplant Lymphoproliferative Disorders Successfully Treated with R-CHOP in Korea
Sul Hee Yoon, Soo Jeong Kim, Hye Won Lee, Doh Yu Hwang, Jin Seok Kim, June-Won Cheong, Yoo Hong Min
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a group of heterogeneous lymphoid diseases that cause serious complications after organ or stem cell transplantation. The onset of PTLD is mostly due to EBV infection-induced B-cell proliferation and a defect in cytotoxic T cell function that occurs with immunosuppression. The usual treatment strategy for PTLD is reduction or withdrawal of immunosuppressive drugs with or without the administration of antiviral agents. Recently, various studies on the efficacy of rituximab or chemotherapy have been reported. We report two cases of rapidly progressing and complicated PTLDs after kidney transplantation that were successfully treated with a combination regimen consisting of rituximab, cyclophosphamide, adriamycin, vincristine and prednisolone (R-CHOP). (Korean J Hematol 2008;43:106-112.)
Keywords: Posttransplant, Lymphoproliferative, R-CHOP
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Chinnawut Suriyonplengsaeng, Pichika Chantrathammachart, Teeraya Puavilai and Suporn Chuncharunee
Blood Res 2024; 59(): -
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
Naohiro Sekiguchi, Airi Hamano, Tomoko Kitagawa, Yuya Kurihara, Kenichi Ito, Miwa Kurimoto, Kozo Watanabe, Kazuhiko Hirano, Satoshi Noto, Kazuaki Yamada, and Naoki Takezako
Blood Res 2018; 53(2): 117-122 -
A Case of Primary Tracheal Lymphoma of a 65-year-old Female: Extremely Rare Primary Localization of a Diffuse Large B-cell Lymphoma
You Sang Ko, Yu Jin Lim, Jae Hoon Yang, Chan Soo So, Mi Jeong Kim, Su Hee Park, Sarah Park, Mi Na Huh, Jung Han Kim, Chul Hong Kim, Jung Won Shim, Hee Sung Hwang, Young Iee Park, Joo Young Jung
Korean J Hematol 2007; 42(4): 439-443
